A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: SHR-A1811：Pyrotinib|DRUG: SHR-A1811；Pertuzumab|DRUG: SHR-A1811；Adebrelimab|DRUG: SHR-A1811；Albumin paclitaxel
Sponsor: Jiangsu HengRui Medicine Co., Ltd.